美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.74

-0.3858-1.10%

成交量：1.96萬

成交額：68.19萬

市值：9,657.72萬

市盈率：- -

高：35.13

開：35.13

低：34.63

收：35.13

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：1.07

換手率：0.71%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

吉利德科學攜手泛美衞生組織，加速拉美及加勒比地區HIV預防藥物Lenacapavir的可及性

吉利德高管表示，未來幾個季度HIV市場增長或將回歸2%-3%常態水平

吉利德高管透露：周服HIV預防藥物有望2027年第一季度上市

市場消息：美國食品藥品監督管理局啓動加速新藥臨床試驗申請試點項目，開始受理相關申請。

石藥創新：SYS6010再獲突破性治療認定 III期臨床試驗正在開展

創新藥「一日遊」？華寶基金藥ETF、港股通創新藥ETF雙雙回調！基本面仍有支撐：數據讀出+出海邏輯持續驗證

恒瑞醫藥：子公司「注射用瑞卡西單抗」獲批開展III期臨床試驗

恒瑞醫藥(600276.SH)：HRS-4139片獲得藥物臨床試驗批准通知書

恒瑞醫藥：子公司HRS-4139片獲臨床試驗批准

恒瑞醫藥：瑞卡西單抗獲批開展III期臨床試驗

維康藥業(300878.SZ)：黃甲軟肝顆粒獲批開展用於慢性乙型病毒性肝炎肝纖維化的III期臨床試驗

維康藥業：黃甲軟肝顆粒獲III期臨床試驗補充申請批准

興齊眼藥(300573.SZ)：SQ-25012注射液獲得臨床試驗批准通知書

興齊眼藥：SQ-25012注射液獲臨床試驗批准通知書

港股異動 | 海西新藥(02637)升逾3% 近期已遞交HX9428的DME IIa期新藥臨床試驗申請

市場持續縮量或臨近變盤，網絡安全概念與創新藥成結構性亮點

智通港股早知道 | 國產創新藥WCLC數據密集兑現投行看好中國CRO/CDMO復甦明確

對外授權交易總額約1100億美元！2026年上半年創新藥「出海」觀察：多款獲批生物類似藥寄望海外收入超越國內

每日经济新闻

創新藥板塊迎來近一個月最大漲幅，這些國產創新藥在「2026世界肺癌大會」讀出亮眼數據

每日经济新闻

CRO板塊強勢走高！多家CRO上市公司解密業務近況

微博财经-财道工作室

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/IBBQ/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.74,"timestamp":1789757318883,"preClose":35.1258,"halted":0,"volume":19628,"delay":0,"changeRate":-0.010983379737970271,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"交易中","change":-0.3858,"latestTime":"09-18 14:49:33 EDT","open":35.13,"high":35.13,"low":34.6296,"amount":681905.514276,"amplitude":0.014246,"askPrice":34.78,"askSize":3300,"bidPrice":34.74,"bidSize":700,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789761600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":35.1258,"sharesOutstanding":2520001,"nav":34.34966,"aum":95492089.14966,"dividendRate":0.007395,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.14,"preClose":35.1258,"latestTime":"19:58 EDT","volume":117,"amount":4061.8054,"timestamp":1789689522745,"change":0.0142,"changeRate":0.000404,"amplitude":0},"volumeRatio":1.069467,"impliedVol":0.0452,"impliedVolPercentile":0.0199},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.069467,"shares":2780001,"dividePrice":0.2569,"high":35.13,"amplitude":0.014246,"preClose":35.1258,"low":34.6296,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.74,"committee":-0.65,"eps":0,"divideRate":0.007395,"volume":19628,"delay":0,"ttmEps":0,"open":35.13,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.472,"twentyDayClose":35.8,"sixtyDayClose":31.2119},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1159280995","title":"吉利德科學攜手泛美衞生組織，加速拉美及加勒比地區HIV預防藥物Lenacapavir的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1159280995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159280995?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485009,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）日前宣布，与泛美卫生组织（PAHO）达成一项战略合作。此番联手，旨在显著提升一年两针的HIV预防药物Lenacapavir在拉丁美洲及加勒比地区的可及性。双方的合作，将为该区域的高风险人群带来更便捷的预防选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU1023059063.AUD","IE00B7SZLL34.SGD","LU0859254822.USD","LU0965508806.USD","BIB","LU1674673428.USD","IBBQ","IE00B19Z3581.USD","LU1057294990.SGD","LU1037948541.HKD","LU0058720904.USD","LU0823416689.USD","LU1674673691.USD","LU1585245621.USD","LU1778281490.HKD","LU1839511570.USD","LU1934455194.USD","LU1037948897.HKD","LU2112291526.USD","SG9999015945.SGD","LU2324357040.USD","LU0965509283.SGD","LU1934455277.USD","SG9999015952.SGD","SG9999015986.USD","LU1571399168.USD","IE00B19Z3B42.SGD","BMED","LU0861579265.USD","BK4583","LU0965509010.AUD","LU0289739699.SGD","LU0114720955.EUR","IE00B3T34201.USD","LU0882574055.USD","BBH","BK4139","BK4566","BK4585","IE00BSNM7G36.USD","LU1061106388.HKD","IBB","LU1430594728.SGD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","TBXU","GILD","LU2357627491.SGD","SG9999015978.USD","LU0320765992.SGD","LU1066053197.SGD","BK4532","TMED","BK4578","LU1066051498.USD","LU0122379950.USD","LU1934455863.HKD","LU2468319806.SGD","BK4588","LU0965509101.SGD","LU0109394709.USD","LU0889565916.HKD","MEDI","LU2087621335.USD","LU2089984988.USD","BK4568","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153389014","title":"吉利德高管表示，未來幾個季度HIV市場增長或將回歸2%-3%常態水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1153389014","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153389014?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:09","pubTimestamp":1789484948,"startTime":"0","endTime":"0","summary":"吉利德高管在电话会议中透露，该公司预计HIV治疗市场的增长势头将在未来几个季度内逐步趋于稳定，最终回到2%至3%的年增长区间。这一表态正值市场对HIV药物需求持续波动的关键节点。高管指出，当前的增长水平仍高于长期趋势，但随着时间推移，这种偏热的状态将逐渐降温。整个行业的扩张速度，预计将在近期内回落至更为可持续的轨道上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","LU2087621335.USD","IBB","GILD","LU0882574055.USD","LU0058720904.USD","LU0861579265.USD","BK4550","BMED","IE00B19Z3581.USD","LU0122379950.USD","LU0234570918.USD","LU1585245621.USD","TBXU","LU1066053197.SGD","LU1839511570.USD","LU1934455194.USD","BK4566","BBH","LU0965509101.SGD","LU1061106388.HKD","LU0109394709.USD","LU1674673428.USD","IBBQ","IE00BKVL7J92.USD","LU1037948897.HKD","BK4139","LU2112291526.USD","LU2357627491.SGD","IE00BSNM7G36.USD","BK4532","LU0114720955.EUR","LU0289739699.SGD","MEDI","LU1037948541.HKD","BIB","LU1778281490.HKD","SG9999015986.USD","LU1571399168.USD","LU0965509283.SGD","SG9999015978.USD","IE0002270589.USD","BK4583","LU1430594728.SGD","LU1934455277.USD","LU2468319806.SGD","IE00B7SZLL34.SGD","LU0965509010.AUD","BK4585","LU2089984988.USD","LU0965508806.USD","IE00BZ1G4Q59.USD","BK4588","LU0823416689.USD","LU0859254822.USD","LU1066051498.USD","LU1934455863.HKD","LU1023059063.AUD","SG9999015945.SGD","LU1057294990.SGD","LU0889565916.HKD","SG9999015952.SGD","TMED","LU1674673691.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","BK4568","LU0320765992.SGD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131138631","title":"吉利德高管透露：周服HIV預防藥物有望2027年第一季度上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1131138631","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131138631?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:05","pubTimestamp":1789484737,"startTime":"0","endTime":"0","summary":"吉利德科学高管在电话会议中表示，其每周口服HIV预防药物预计将于2027年第一季度正式推出。这一表态为公司抗艾药物管线注入了新的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU1066051498.USD","LU1585245621.USD","BK4550","LU0289739699.SGD","SG9999015952.SGD","BK4139","BIB","IBBQ","LU0823416689.USD","BK4585","IE00B7SZLL34.SGD","LU0109394709.USD","LU1674673428.USD","SG9999015978.USD","LU0859254822.USD","BK4588","BK4578","LU0058720904.USD","SG9999015945.SGD","LU2357627491.SGD","LU1037948541.HKD","LU0234570918.USD","LU0965509010.AUD","LU1674673691.USD","LU0114720955.EUR","MEDI","LU1061106388.HKD","LU1023059063.AUD","LU1934455277.USD","IE00B19Z3581.USD","LU1057294990.SGD","LU1571399168.USD","BK4568","IE0002270589.USD","BK4583","IE00B3T34201.USD","LU2468319806.SGD","LU0122379950.USD","LU2087621335.USD","LU1934455194.USD","LU0965509283.SGD","LU1839511570.USD","LU2324357040.USD","LU0889565916.HKD","LU2112291526.USD","GILD","BK4532","LU0965508806.USD","LU1934455863.HKD","LU1430594728.SGD","SG9999015986.USD","TBXU","LU0861579265.USD","IBB","IE00BSNM7G36.USD","LU0320765992.SGD","LU1037948897.HKD","IE00BZ1G4Q59.USD","LU1066053197.SGD","BK4566","TMED","LU0965509101.SGD","LU1778281490.HKD","LU2089984988.USD","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","BBH","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667362891","title":"市場消息：美國食品藥品監督管理局啓動加速新藥臨床試驗申請試點項目，開始受理相關申請。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667362891","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667362891?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 22:09","pubTimestamp":1789481392,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","IBBQ","PSYK","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667264193","title":"石藥創新：SYS6010再獲突破性治療認定 III期臨床試驗正在開展","url":"https://stock-news.laohu8.com/highlight/detail?id=2667264193","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667264193?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 19:08","pubTimestamp":1789470480,"startTime":"0","endTime":"0","summary":"中证智能财讯石药创新(300765)9月15日晚间公告，公司控股子公司石药集团巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，拟定适应症为免疫及含 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260915/c679932866.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260915/c679932866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["IBBJ","IBBQ","BK0226","MDTX","BMED","PSYK","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667964132","title":"創新藥「一日遊」？華寶基金藥ETF、港股通創新藥ETF雙雙回調！基本面仍有支撐：數據讀出+出海邏輯持續驗證","url":"https://stock-news.laohu8.com/highlight/detail?id=2667964132","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667964132?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 19:04","pubTimestamp":1789470240,"startTime":"0","endTime":"0","summary":"逆市大涨之后，9月15日，A+H创新药短线迎来回调，药ETF华宝、港股通创新药ETF华宝标的指数分别收跌0.8%、1.48%。创新药龙头数据读出。出海逻辑持续验证。逢跌埋伏创新药，关注两大投资工具：港股通创新药ETF华宝：紧密跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，前十大权重股占比超七成，龙头属性突出，底层资产是港股，高弹性、T+0。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-15/doc-inirxhzq8476737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","159316","BK1574","159992","06978","IBBQ","FLHK","MEDX","BK4550","FDN","LNGR","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667648964","title":"恒瑞醫藥：子公司「注射用瑞卡西單抗」獲批開展III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667648964","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667648964?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:55","pubTimestamp":1789462500,"startTime":"0","endTime":"0","summary":"9月15日，恒瑞医药（600276/01276）发布公告，公司子公司广东恒瑞药有限公司近日收到国家药品监督管理局核准签发的关于注射用瑞卡西单抗的《药物临床试验批准通知书》，将于近期开展III期临床试验。该药物的适应症为颅内动脉粥样硬化性狭窄的成人患者，以降低卒中复发风险。2026年中期，恒瑞医药实现收入154.56亿元，归母净利润44.65亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153874740380.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153874740380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","LU1997245094.SGD","LU2097828714.EUR","BK0183","LU0359201885.HKD","LU2097828805.USD","BK0196","LU1655091616.SGD","BK0012","BK0188","BK1191","LU0405327148.USD","LU0359202008.SGD","PSYK","LU2495084118.USD","LU0359201612.USD","LU2488822045.USD","LU1146622755.USD","BK0060","LU1997245177.USD","LU2580892789.USD","LU1997244956.HKD","LU2580892862.HKD","01276","LU1255011170.USD","LU2097828557.USD","LU1064130708.USD","LU2097828474.EUR","LU1023057109.AUD","600276","LU2289578879.USD","IBBJ","LU1064131003.USD","LU1328615791.USD","LU1820825898.SGD","MDTX","LU1781817850.SGD","BK0239","IBBQ","LU1580142542.USD","BMED","LU0405327494.USD","LU2148510915.USD","LU2328871848.SGD","LU2543165471.USD","LU2097828631.EUR","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667610471","title":"恒瑞醫藥(600276.SH)：HRS-4139片獲得藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667610471","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667610471?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:39","pubTimestamp":1789461583,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-4139片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-4139片是公司自主研发的1类新药，在动物模型中，可有效改善银屑病症状，抑制炎症反应。经查询，国内外暂无相同靶点药物获批上市。截至目前，HRS-4139片相关项目累计研发投入约2,040万元(未经审计)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","BK0183","BK0028","LU0405327494.USD","LU1064130708.USD","LU2495084118.USD","MDTX","LU1255011170.USD","01276","LU1997245094.SGD","LU2097828631.EUR","LU0359201612.USD","LU1655091616.SGD","IBBJ","LU1969619763.USD","LU2488822045.USD","LU1328615791.USD","BK0239","LU1023057109.AUD","LU1146622755.USD","BK0012","BK1191","LU2580892789.USD","LU1997245177.USD","LU0359202008.SGD","LU2580892862.HKD","BK0060","LU0405327148.USD","LU0359201885.HKD","BK0188","LU2097828474.EUR","LU2097828805.USD","LU1580142542.USD","600276","LU2289578879.USD","LU1781817850.SGD","LU2148510915.USD","LU1997244956.HKD","LU2097828714.EUR","IBBQ","LU2097828557.USD","LU2328871848.SGD","LU2543165471.USD","LU1064131003.USD","BK0196","LU1820825898.SGD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667610193","title":"恒瑞醫藥：子公司HRS-4139片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667610193","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667610193?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:35","pubTimestamp":1789461321,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","BMED","MDTX","IBBQ","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667101906","title":"恒瑞醫藥：瑞卡西單抗獲批開展III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667101906","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667101906?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:35","pubTimestamp":1789461310,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","MDTX","PSYK","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667832610","title":"維康藥業(300878.SZ)：黃甲軟肝顆粒獲批開展用於慢性乙型病毒性肝炎肝纖維化的III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667832610","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667832610?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:15","pubTimestamp":1789460131,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维康药业(300878.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的黄甲软肝颗粒的《药物临床试验补充申请批准通知书》，经审查，黄甲软肝颗粒临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意开展用于慢性乙型病毒性肝炎肝纤维化的III期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","MDTX","300878","IBBJ","BK0239","BMED","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667661724","title":"維康藥業：黃甲軟肝顆粒獲III期臨床試驗補充申請批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667661724","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667661724?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:07","pubTimestamp":1789459662,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBJ","IBBQ","PSYK","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617527","title":"興齊眼藥(300573.SZ)：SQ-25012注射液獲得臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617527","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667617527?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 15:54","pubTimestamp":1789458841,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布公告，近日，公司收到国家药品监督管理局签发的关于SQ-25012注射液的《药物临床试验批准通知书》，同意本品开展拟用于治疗甲状腺眼病的临床试验。SQ-25012注射液是一款重组人源化IgG1型三特异性抗体，为公司研发的治疗用生物制品1类创新药，临床拟用于治疗甲状腺眼病。根据创新型治疗用生物制品1类注射剂的有关要求，公司已经完成SQ-25012注射液药学及非临床药理毒理学等多方面的研究，研究结果表明SQ-25012注射液具有良好的安全性及临床开发价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0239","300573","PSYK","BMED","BK0177","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617589","title":"興齊眼藥：SQ-25012注射液獲臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617589","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667617589?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 15:51","pubTimestamp":1789458674,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","BMED","MDTX","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667148376","title":"港股異動 | 海西新藥(02637)升逾3% 近期已遞交HX9428的DME IIa期新藥臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2667148376","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667148376?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 14:48","pubTimestamp":1789454932,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药涨超3%，截至发稿，涨2.89%，报195.5港元，成交额618.26万港元。消息面上，海西新药发布公告，本公司自主研发的创新药项目HXP056的候选药物分子HX9428，已于2026年8月31日正式向中国国家药品监督管理局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。公司表示，将继续全力推进HX9428在中美两地多项临床研究的进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","KCAI","MDTX","PSYK","BMED","BK1191","BK4585","02637","VXUS","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667697929","title":"市場持續縮量或臨近變盤，網絡安全概念與創新藥成結構性亮點","url":"https://stock-news.laohu8.com/highlight/detail?id=2667697929","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667697929?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 09:28","pubTimestamp":1789435718,"startTime":"0","endTime":"0","summary":"　　昨日市场延续弱势震荡，三大指数全线收跌，量能进一步萎缩，仅剩1.63万亿，通常而言持续缩量震荡后市场面临着变盘节点，静待后续的方向选择。　　网络安全概念成为昨日市场最大亮点，逆势走出独立走强行情。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/zldongxiang/20260915/32369725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BPAY","WCBR","BUG","IHAK","TEKX","BK1574","GSFP","SKYY","UCYB","FWD","CRWL","INVN","TEKY","BK4585","MVPS","CRTC","EIS","TEK","BK1161","06978","LOUP","NBDS","LNGR","PSWD","CIBR","SPAM","ANEW","NSI","PSCT","MEDX","159992","USMD","FITE","KOMP","BK4588","DRES","FDFF","CRWC","XT","FDIF","BCTK","HAKY","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691412","title":"智通港股早知道 | 國產創新藥WCLC數據密集兑現 投行看好中國CRO/CDMO復甦明確","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667691412?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 07:29","pubTimestamp":1789428595,"startTime":"0","endTime":"0","summary":"WCLC临床数据密集兑现，国内外投行相继看好中国CRO/CDMO复苏明确9月12日至15日，2026年世界肺癌大会在韩国首尔举行，多项国产创新药临床数据集中亮相，中国新药入选口头报告19项、小型口头报告45项，双双刷新历史纪录，肺癌领域ADC与双抗数据成为焦点。经初步测算，本次交易完成后，一汽股份将成为公司第二大和具有战略影响力的股东;本次交易预计构成重大资产重组及关联交易，不构成公司实际控制人变更，不构成重组上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B543WZ88.USD","IE0008369823.USD","KCAI","06871","BK1574","LU1226288170.HKD","LU1993786604.SGD","BK4585","06978","BK1147","BK1161","LU1226287875.USD","IE00BZ08YT58.USD","LU1008478684.HKD","LNGR","LU0315179316.USD","BK1144","LU0501845795.SGD","VXUS","01093","LU1951186391.HKD","LU0314109678.HKD","LU1960683339.HKD","BK1183","LU1152091754.HKD","LU1226287529.USD","LU0326950275.SGD","02889","LU2039709279.SGD","MEDX","159992","LU1813983027.USD","IE0008368742.USD","CDMO","BK1539","BK4588","IE00B5MMRT66.SGD","KURE","BK1191","01911","02238","BK1119","BK4139","HK0000165453.HKD","LU0140636845.USD","LU1226287792.SGD","SG9999004220.SGD","LU1328277881.USD","BK1521","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667660668","title":"對外授權交易總額約1100億美元！2026年上半年創新藥「出海」觀察：多款獲批生物類似藥寄望海外收入超越國內","url":"https://stock-news.laohu8.com/highlight/detail?id=2667660668","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667660668?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 01:03","pubTimestamp":1789405401,"startTime":"0","endTime":"0","summary":"2026年上半年，中国创新药延续高增长态势。国家药监局数据显示，2026年1~6月，中国创新药对外授权交易共81笔，总额约1100亿美元，已达2025年全年总额的八成，创历史新高。《每日经济新闻》记者（以下简称每经记者）注意到，从上市公司半年报来看，首付款作为部分企业BD（商务拓展）收入的一部分，让利润表短暂“翻红”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153873800338.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153873800338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBB","06978","LU2272731865.HKD","IBBQ","LU1992135472.HKD","159992","LU2322448791.USD","MEDX","PPH","BK1161","BK1574","LU2272731782.SGD","BK4585","LU2473716301.USD","LU2272731600.USD","LU1992135399.USD","XPH","LNGR","IE00B5TLWC47.USD","LU2322448957.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667366424","title":"創新藥板塊迎來近一個月最大漲幅，這些國產創新藥在「2026世界肺癌大會」讀出亮眼數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2667366424","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667366424?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 22:40","pubTimestamp":1789396854,"startTime":"0","endTime":"0","summary":"9月14日，低迷了近一个月的创新药板块迎来上涨。截至收盘，创新药（BK1106）、创新药（HK1105）分别上涨2.38%、3.42%。个股方面，诺诚健华、映恩生物、乐普生物、康方生物领跑港股。消息面上，9月12日—15日召开的“2026世界肺癌大会（WCLC）”成为板块最强催化，多家国产药企密集交出重磅临床数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873752330.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873752330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MEDX","LNGR","BK1574","IBBQ","06978","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667466104","title":"CRO板塊強勢走高！多家CRO上市公司解密業務近況","url":"https://stock-news.laohu8.com/highlight/detail?id=2667466104","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667466104?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 21:08","pubTimestamp":1789391280,"startTime":"0","endTime":"0","summary":"在互动平台与机构调研中，多家具备CRO业务的上市公司近期密集回应市场关切，披露了订单、产能及全球化布局的最新进展。2026 年上半年，公司实现 CRO 销售收入 4,513.95 万元， 较上年同期增长 10.91%。截至 2026 年上半年末，客户群体不断扩大，累计服务超过 16,900 家研发实验室客户。CRO 业务毛利率基本保持相对稳定水平，具体受服务类型、项目内容影响有所波动。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-09-14/doc-inirveaq9305051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NETL","BK1574","MEDX","LNGR","ADC","BK4080","BK1161","IBBQ","BK4231","06978"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":4,"totalSize":219,"code":"91000000","status":"200"}]}}